Literature DB >> 12367647

Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence.

Hartwig W Lehmann1, Lucia Kühner, Karin Beckenlehner, Esther Müller-Godeffroy, Karl-Günter Heide, Rolf-Michael Küster, Susanne Modrow.   

Abstract

Parvovirus B19 causes erythema infectiosum in children, but the virus is associated with an increasing range of different diseases. About 20% of infections are associated with delayed virus elimination and viremia persisting over several months or years. These persistent B19-infections are characterised by the presence of IgG against the non-structural protein NS1. This study aimed to find further evidence for an association of parvovirus B19 persistence with VP1/2- and NS1-specific IgG-antibodies in children suffering from rheumatic diseases of childhood. Forty-eight children and adolescents with joint complaints lasting longer than 1 year including patients with juvenile systemic sclerosis and juvenile dermatomyositis showed antibodies against the viral NS1-protein. Laboratory markers of inflammation, humoral immune response against parvovirus B19 proteins and the presence of viral genomes in patients' sera as well as in 124 healthy children were investigated. Almost 50% of the patients showed laboratory signs of chronic inflammation. B19-DNA was amplified in 31% of patients' sera and 7% of the controls (P<0.0001). VP2-specific IgM was detectable in 50% of the patients' and 6% of control sera. NS1-specific immune reactions were linked to persistent B19-infection as indicated by the presence of viral genomes in the peripheral blood and of VP2-specific IgM years after disease onset. To estimate the severity of the disease and the clinical course, the number of affected and functionally impaired joints were noted and compared with the records from patients' initial visit in the hospital. Disease related complications were registered. Impairment of activities of daily living was assessed by Childhood Health Assessment Questionnaire (CHAQ)- and Munich Quality of Life Questionnaire (KINDL)-tests. During observation the clinical state of four patients worsened, 27 improved, the others remained stable. Twenty-four children were restricted in their daily activities.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12367647     DOI: 10.1016/s1386-6532(01)00247-5

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  10 in total

Review 1.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 2.  Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications.

Authors:  Mirella De Civita; Dean Regier; Abul H Alamgir; Aslam H Anis; Mark J Fitzgerald; Carlo A Marra
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Diagnosis and management of infectious complications of childhood rheumatic diseases.

Authors:  Rhina D Castillo; Wendy De la Pena; Katherine A B Marzan
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

4.  Oligoclonal expansion of circulating and tissue-infiltrating CD8+ T cells with killer/effector phenotypes in juvenile dermatomyositis syndrome.

Authors:  K Mizuno; A Yachie; S Nagaoki; H Wada; K Okada; M Kawachi; T Toma; A Konno; K Ohta; Y Kasahara; S Koizumi
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

5.  Intravenous immunoglobulin treatment of four patients with juvenile polyarticular arthritis associated with persistent parvovirus B19 infection and antiphospholipid antibodies.

Authors:  Hartwig W Lehmann; Annelie Plentz; Philipp Von Landenberg; Esther Müller-Godeffroy; Susanne Modrow
Journal:  Arthritis Res Ther       Date:  2003-10-10       Impact factor: 5.156

Review 6.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

7.  Different patterns of disease manifestations of parvovirus B19-associated reactive juvenile arthritis and the induction of antiphospholipid-antibodies.

Authors:  Hartwig W Lehmann; Annelie Plentz; Philipp von Landenberg; Rolf-M Küster; Susanne Modrow
Journal:  Clin Rheumatol       Date:  2007-09-13       Impact factor: 3.650

8.  Seroprevalence of parvovirus B19 IgG in children affected by juvenile idiopathic arthritis.

Authors:  Benedikt Weissbrich; Yvonne Süss-Fröhlich; Hermann J Girschick
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 9.  Role of capsid proteins in parvoviruses infection.

Authors:  Mengyu Tu; Fei Liu; Shun Chen; Mingshu Wang; Anchun Cheng
Journal:  Virol J       Date:  2015-08-04       Impact factor: 4.099

10.  Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus.

Authors:  Ashleigh Manning; Samantha J Willey; Jeanne E Bell; Peter Simmonds
Journal:  J Infect Dis       Date:  2007-03-21       Impact factor: 5.226

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.